MSLN and neoplasm: A phase I study evaluated gavo-cel in previously treated mesothelin-expressing (defined as 2+ or 3+ mesothelin expression by IHC staining in ≥50% of tumor cells) solid tumor patients, 23 of whom had PM [72].